Portal Innovations
VC Fund
Chicago, United States
Portal Innovations is a VC fund in Chicago focused on Biotechnology and Medical. Portal Innovations invests in therapeutics, med tech, and bioinformatics startups with strong leadership teams.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Portal Innovations invests in
Stages Portal Innovations invests in
Countries Portal Innovations invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John L. Flavin
|
|||
Investment Focus
Industry
- Biotechnology 9 (60%)
- Medical 8 (53%)
- Health Care 6 (40%)
- Therapeutics 3 (20%)
- Wearables 2 (13%)
Stage
- Series A 8 (53%)
- Seed 6 (40%)
- Pre-Seed 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
John L. Flavin
Founder & CEO
|
Founder & CEO | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SyntaxBio
|
SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention. | $14.4M / Series A / Jun 21, 2026 | |
Syntis Bio
|
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $33M / Series A / Jul 01, 2025 | |
Vincere Biosciences
|
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M / Series A / Apr 01, 2025 | |
Synaptrix
|
Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC. | $10M / Series A / Nov 15, 2024 | |
CrossBridge Bio
|
CrossBridge Bio operates as a biotechnology company, innovates ADC therapeutics through stable dual linker payload technology. | $10M / Seed / Nov 04, 2024 | |
March Biosciences
|
March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M / Series A / Oct 23, 2024 | |
|
SyntaxBio
|
SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention. | Seed / Sep 17, 2024 | |
Moonlight Therapeutics
|
Moonlight Therapeutics is focused on developing safe, effective, and patient-friendly treatments for people suffering from food allergies. | $2.4M / Seed / Aug 15, 2024 | |
Alnair Therapeutics
|
Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult-to-treat malignancies. It has created a first-of-its-kind drug delivery technology that uses the unique features of cancer metabolism to improve drug targeting and penetration directly into cancer cells, henceenhancing patient treatment outcomes. | $1M / Pre-Seed / Jun 30, 2023 | |
Dimension Inx
|
Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois. | $12M / Series A / Feb 01, 2023 | |
| See all 15 investments → | |||
Co-Investors
Alexandria Venture Investments
2 deals together
Alumni Ventures
2 deals together
Astellas Venture Management
2 deals together
Bold Capital Partners
2 deals together
Colorcon Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Portal Innovations invest in?
Portal Innovations invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Portal Innovations?
Public channels for Portal Innovations include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Portal Innovations?
The team at Portal Innovations includes John L. Flavin (Founder & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
